Individualization of immunosuppressive protocols has been explored as a strategy to reduce infectious complications, including CMV infection, particularly through selective use of non-depleting induction agents [34, 35] or mTOR inhibitors [36, 37]. Here, MTOR is linked to cytomegalovirus infection.